Expertise in
22
conditions

Dr. Nabil Adra

Hematology Oncology | Hematology | Oncology
University Medical Diagnostic Associates Inc
535 Barnhill Dr, 
Indianapolis, IN 
Clinical Trials:Currently Recruiting for 4 Trials
Accepting New Patients
Offers Telehealth
Expertise in
22
conditions
University Medical Diagnostic Associates Inc
535 Barnhill Dr, 
Indianapolis, IN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Nabil Adra is a Hematologist Oncology specialist and a Hematologist in Indianapolis, Indiana. Dr. Adra is highly rated in 22 conditions, according to our data. His top areas of expertise are Testicular Cancer, Teratoma of the Mediastinum, Prostate Cancer, Orchiectomy, and Bone Marrow Transplant. Dr. Adra is currently accepting new patients.

His clinical research consists of co-authoring 92 peer reviewed articles and participating in 16 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in IN
Hospital Affiliations
Indiana University Health Bloomington Hospital
Indiana University Health
Indiana University Health Ball Memorial Hospital
Iu Health West Hospital
Indiana University Health North Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Anthem
  •  CareSource
  •  Humana

Locations

UNIVERSITY MEDICAL DIAGNOSTIC ASSOCIATES INC
535 Barnhill Dr, Indianapolis, IN 46202

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer
A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer
Enrollment Status: Recruiting
Publish Date: April 10, 2025
Intervention Type: Drug
Study Drug: ARX517 Anti-PSMA AS269-Conjugated Monoclonal Antibody
Study Phase: Phase 1
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
Enrollment Status: Recruiting
Publish Date: March 19, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Bleomycin, Bleomycin Sulfate, Carboplatin, Cisplatin, Etoposide, Etoposide Phosphate
Study Phase: Phase 3
Randomized Phase 2 Trial of Maintenance Oral Etoposide or Observation Following High-dose Chemotherapy for Relapsed Metastatic Germ-Cell Tumor
Randomized Phase 2 Trial of Maintenance Oral Etoposide or Observation Following High-dose Chemotherapy for Relapsed Metastatic Germ-Cell Tumor
Enrollment Status: Recruiting
Publish Date: February 06, 2025
Intervention Type: Drug
Study Phase: Phase 2
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Enrollment Status: Recruiting
Publish Date: August 16, 2024
Intervention Type: Procedure, Drug, Other, Radiation
Study Drugs: Abiraterone, Bicalutamide, Degarelix, Docetaxel, Flutamide, Goserelin acetate, Histrelin acetate, Leuprolide acetate, Nilutamide, Prednisone, Triptorelin
Study Phase: Phase 3
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: April 09, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: April 03, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
A Phase II Trial Evaluating the Efficacy of Cabozantinib in the Treatment of Incurable Patients with Refractory Germ Cell Tumors
A Phase II Trial Evaluating the Efficacy of Cabozantinib in the Treatment of Incurable Patients with Refractory Germ Cell Tumors
Enrollment Status: Active_not_recruiting
Publish Date: March 24, 2025
Intervention Type: Drug
Study Phase: Phase 2
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2025
Intervention Type: Drug, Other, Radiation
Study Drugs: Bicalutamide, Docetaxel, Flutamide, Goserelin acetate, Leuprolide acetate, Nilutamide
Study Phase: Phase 2/Phase 3
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Enrollment Status: Active_not_recruiting
Publish Date: March 05, 2025
Intervention Type: Drug
Study Drugs: 177Lu-PSMA-617, Androgen Receptor Directed Therapy, Androgen Deprivation Therapy
Study Phase: Phase 3
A Prospective Observational Cohort Study to Assess MiRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors
A Prospective Observational Cohort Study to Assess MiRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 26, 2025
Intervention Type: Procedure, Other
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Enrollment Status: Active_not_recruiting
Publish Date: January 29, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Abiraterone acetate, Antiandrogen therapy, Cabazitaxel, Prednisone
Study Phase: Phase 2
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: January 22, 2025
Intervention Type: Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy
A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy
Enrollment Status: Active_not_recruiting
Publish Date: May 24, 2024
Intervention Type: Drug
Study Drugs: 177Lu-J591, Ketoconazole, Hydrocortisone, 111In-J591
Study Phase: Phase 2
Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302)
Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302)
Enrollment Status: Terminated
Publish Date: March 13, 2024
Intervention Type: Drug
Study Drug: Infigratinib
Study Phase: Phase 3
A Phase II Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 Inhibitor in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: HCRN GU17-295
A Phase II Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 Inhibitor in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: HCRN GU17-295
Enrollment Status: Terminated
Publish Date: September 13, 2023
Intervention Type: Drug
Study Drugs: Carboplatin, Gemcitabine, Atezolizumab, Docetaxel
Study Phase: Phase 2
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: May 11, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 12 Less Clinical Trials

86 Total Publications

Measurement of Patients' Acceptable Symptom Levels and Priorities for Symptom Improvement in Advanced Prostate Cancer.
Measurement of Patients' Acceptable Symptom Levels and Priorities for Symptom Improvement in Advanced Prostate Cancer.
Journal: Research square
Published: October 07, 2024
Similar Doctors
Nasser H. Hanna
Expertise in
18
conditions
Dr. Nasser H. Hanna
Oncology | Hematology Oncology | Hematology
Expertise in
18
conditions
Dr. Nasser H. Hanna
Oncology | Hematology Oncology | Hematology

University Medical Diagnostic Associates Inc

11700 N Meridian St, Clarion North Medical Cente, 
Carmel, IN 
 (12.7 mi)
317-274-8660
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nasser Hanna is an Oncologist and a Hematologist Oncology provider in Carmel, Indiana. Dr. Hanna is highly rated in 18 conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Testicular Cancer, Orchiectomy, and Bone Marrow Transplant. Dr. Hanna is currently accepting new patients.

Expertise in
12
conditions
Dr. Patrick J. Loehrer
Hematology Oncology | Oncology | Hematology
Expertise in
12
conditions
Dr. Patrick J. Loehrer
Hematology Oncology | Oncology | Hematology

University Medical Diagnostic Associates Inc

550 N University Blvd, 
Indianapolis, IN 
 (0.1 mi)
217-274-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Patrick Loehrer is a Hematologist Oncology specialist and an Oncologist in Indianapolis, Indiana. Dr. Loehrer is highly rated in 12 conditions, according to our data. His top areas of expertise are Thymic Epithelial Tumor, Colorectal Cancer, Pancreatic Cancer, Pancreaticoduodenectomy, and Thymectomy. Dr. Loehrer is currently accepting new patients.

Bryan P. Schneider
Expertise in
27
conditions
Dr. Bryan P. Schneider
Hematology Oncology | Oncology | Hematology
Expertise in
27
conditions
Dr. Bryan P. Schneider
Hematology Oncology | Oncology | Hematology

University Medical Diagnostic Associates Inc

550 N University Blvd, 
Indianapolis, IN 
 (0.1 mi)
217-274-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Bryan Schneider is a Hematologist Oncology specialist and an Oncologist in Indianapolis, Indiana. Dr. Schneider is highly rated in 27 conditions, according to our data. His top areas of expertise are Breast Cancer, Thymic Epithelial Tumor, Inflammatory Breast Cancer, and Paget Disease of the Breast. Dr. Schneider is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Find Dr. Adra's expertise for a condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile